CureVac NV has released its financial results for the second quarter and first half of 2025, revealing significant changes in its financial performance. The company's revenues for the three and six months ended June 30, 2025, stood at €1.2 million and €2.1 million, respectively, marking a substantial decrease of 91% and 92% compared to €14.4 million and €26.8 million during the same periods in 2024. This decline was primarily due to reduced revenues from GSK, following the restructuring of their partnership into a licensing agreement in July 2024, as well as diminished sales to CRISPR Therapeutics. CureVac reported an operating loss of €61.7 million for the second quarter and €116.5 million for the first half of 2025, representing a decrease from losses of €73.6 million and €146.9 million in the corresponding periods of the previous year. The company attributed these improved results to strategic restructuring, including cost reductions and a workforce reduction initiated in July 2024. Research and development expenses increased, influenced by the reclassification of manufacturing costs as R&D expenses, although this was partially offset by the cost-saving measures. The net financial result for the first half of 2025 was €4.9 million, reflecting a decrease from €5.8 million in the previous year. CureVac's cash position showed a decrease from the end of 2024, with funds primarily allocated to advancing research in oncology precision immunotherapies, prophylactic vaccines, and mRNA technology development. In a significant business update, CureVac announced a definitive Purchase Agreement with BioNTech, which intends to acquire all shares of CureVac. This acquisition aims to unite two complementary German companies to advance mRNA-based treatments globally. CureVac reaffirmed its expected cash runway extending into 2028.